Living with Pancreatic Cancer
730 articles
Can I exercise? How can I cope with stress and anxiety? Learn more here.
Machine-Learning Assay May Improve Pancreatic Cyst Management
Dr. Anne Marie Lennon explains CompCyst, the artificial intelligence-based assay that can determine the best treatment for pancreatic cysts.
Comprehensive Molecular Test Helps Classify Pancreatic Cysts
Dr. Aatur Singhi and colleagues are developing a test to help determine whether pancreatic cysts are likely to turn cancerous.
Most Cancer Mutations Are Random DNA Mistakes
In a large study, Dr. Bert Vogelstein of Johns Hopkins found that a majority of cancers, including pancreatic cancer, are caused by random mutations of DNA.
Finding the Best Diabetes Drug for Pancreatic Cancer Patients
With all the various drugs out there, Dr. James Flory wants to establish which diabetes drug works best for pancreatic cancer patients. Read his expert advice.
What You Should Know About Tumor Boards
A tumor board brings together experts in different treatment fields to discuss your case and help direct your pancreatic cancer treatment.
Drafting Your Health Care Team
If you have pancreatic cancer, a treatment team of experts from across the medical profession will make sure you get the best care.
Lustgarten–AACR Name Career Development Award Winners
The Lustgarten Foundation and AACR announced the winners of the 2022 Ruth Bader Ginsburg and John Robert Lewis Career Development Awards.
Understanding How Super-Enhancers Rev Up Pancreatic Cancer Growth
Researcher Ronald Evans, Ph.D., and his team at the Salk Institute are focusing on how super-enhancers stimulate pancreatic cancer growth.
Pancreatic Cancer Pathology: How Doctors Get to a Diagnosis
Dr. Jingxin Qiu explains the role of pathology in grading a tumor and staging cancer, to help patients understand the pancreatic cancer diagnosis.
Representing Genetic and Clinical Diversity in Pancreatic Cancer
Dr. Kentaro Sudo explores the possible causes for different responses to drugs among ethnic groups, pointing to the need for clinical diversity in trials.